Fig. 2: Overall survival from time of CLL progression on ibrutinib by line of therapy.

A It compares patients who received ibrutinib ast first therapy to those treated with ibrutinib in the relapsed/refractory setting. B It further evaluates the relapsed/refractory cohort by number of prior lines of therapy.